Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Friday 14 September, 2018

Euronext Dublin

GEM Notice

RNS Number : 8736A
Euronext Dublin
14 September 2018
 

 

EURONEXT DUBLIN

 

 

 

 

ADMISSION NOTICE

 

                                   

Euronext Dublin

28 Anglesea Street

Dublin 2

 

 

14th September 2018

 

Euronext Dublin approves the admission of the undermentioned securities to listing on the Official List and trading on the Global Exchange Market.

 

 

ASSURANT CLO III, LTD.

 

USD 4600000 Class X Senior Secured Floating Rate Notes due 2031 (Reg S) USG23871AA73

USD 23450000 Class C Mezzanine Secured Deferrable Floating Rate Notes due 2031 (144A) US04624WAG24

USD 30150000 Class D Mezzanine Secured Deferrable Floating Rate Notes due 2031 (Reg S) USG23871AE95

USD 296700000 Class A Senior Secured Floating Rate Notes due 2031 (Reg S) USG23871AB56

USD 46950000 Class B Senior Secured Floating Rate Notes due 2031 (144A) US04624WAE75

USD 23450000 Class C Mezzanine Secured Deferrable Floating Rate Notes due 2031 (Reg S) USG23871AD13

USD 4600000 Class X Senior Secured Floating Rate Notes due 2031 (144A) US04624WAA53

USD 30150000 Class D Mezzanine Secured Deferrable Floating Rate Notes due 2031 (144A) US04624WAJ62

USD 46950000 Class B Senior Secured Floating Rate Notes due 2031 (Reg S) USG23871AC30

USD 25870000 Class E Junior Secured Deferrable Floating Rate Notes due 2031 (144A) US04624XAA37

USD 25870000 Class E Junior Secured Deferrable Floating Rate Notes due 2031 (Reg S) USG23870AA90

USD 296700000 Class A Senior Secured Floating Rate Notes due 2031 (144A) US04624WAC10

 

Debt Security - Final Terms

 

This announcement has been issued through the Companies Announcement Service of

Euronext Dublin.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEZZLFFVKFEBBZ

a d v e r t i s e m e n t